Patents by Inventor Edmund V. Dennett

Edmund V. Dennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250228888
    Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
    Type: Application
    Filed: April 7, 2025
    Publication date: July 17, 2025
    Inventors: Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
  • Publication number: 20250186484
    Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
    Type: Application
    Filed: February 25, 2025
    Publication date: June 12, 2025
    Inventors: Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
  • Patent number: 12290529
    Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: May 6, 2025
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
  • Patent number: 12239659
    Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
    Type: Grant
    Filed: June 14, 2024
    Date of Patent: March 4, 2025
    Inventors: Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
  • Publication number: 20240415876
    Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
    Type: Application
    Filed: August 2, 2024
    Publication date: December 19, 2024
    Inventors: Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
  • Publication number: 20240415875
    Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
    Type: Application
    Filed: June 14, 2024
    Publication date: December 19, 2024
    Inventors: Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
  • Publication number: 20240325436
    Abstract: Disclosed herein are compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed compositions can comprise a flavoring agent and polyethylene glycol. The disclosed compositions are superior to prior art compositions in that the disclosed compositions allow for higher tolerability, lower volumes, and improved patient compliance. In some embodiments, the composition comprises non-fermentable carbohydrates. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: June 11, 2024
    Publication date: October 3, 2024
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark Cleveland, Edmund V. Dennett, JR., Russell W. Pelham, Matthew Walker
  • Publication number: 20230263733
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: May 1, 2023
    Publication date: August 24, 2023
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Publication number: 20230256010
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: April 26, 2023
    Publication date: August 17, 2023
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Patent number: 11638697
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: May 2, 2023
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, Jr., Russell W Pelham
  • Patent number: 11382864
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: July 12, 2022
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, Jr., Russell W Pelham
  • Publication number: 20210299050
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Publication number: 20210290546
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 23, 2021
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Patent number: 11033498
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: June 15, 2021
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, Jr., Russell W. Pelham
  • Publication number: 20200352855
    Abstract: Disclosed herein are compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed compositions can comprise a flavoring agent and polyethylene glycol. The disclosed compositions are superior to prior art compositions in that the disclosed compositions allow for higher tolerability, lower volumes, and improved patient compliance. In some embodiments, the composition comprises non-fermentable carbohydrates. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: May 9, 2019
    Publication date: November 12, 2020
    Applicant: Sebela Pharmaceuticals, Inc.
    Inventors: Mark Cleveland, Edmund V. Dennett, JR., Russell W. Pelham, Matthew Walker
  • Publication number: 20190099375
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: December 3, 2018
    Publication date: April 4, 2019
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Patent number: 10143656
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 4, 2018
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, Jr., Russell W. Pelham
  • Publication number: 20180207200
    Abstract: The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
    Type: Application
    Filed: January 31, 2018
    Publication date: July 26, 2018
    Applicant: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, JR., David S. Wells
  • Patent number: 9919007
    Abstract: The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 20, 2018
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Jr., David S. Wells
  • Publication number: 20170182090
    Abstract: The present invention is generally directed to an oral pharmaceutical composition comprising a sulfate salt, for example, sodium sulfate and/or potassium sulfate, wherein the composition is substantially free of magnesium sulfate. The present invention is further directed to use of such oral pharmaceutical compositions to induce laxation or to treat or prevent constipation, e.g., opioid-induced constipation.
    Type: Application
    Filed: March 11, 2017
    Publication date: June 29, 2017
    Inventors: Mark vB Cleveland, John S. Fordtran, Edmund V. Dennett